AIM ImmunoTech Unveils Promising Clinical Data on Ampligen's Impact in Late-Stage Pancreatic Cancer and Endometriosis at International Symposium
Reuters
Aug 06, 2025
AIM ImmunoTech Unveils Promising Clinical Data on Ampligen's Impact in Late-Stage Pancreatic Cancer and Endometriosis at International Symposium
AIM ImmunoTech Inc. has announced that the clinical successes of its drug Ampligen in oncology will be highlighted at the upcoming 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland. The presentations will cover various aspects, including ongoing clinical programs in late-stage pancreatic cancer and Ampligen's potential therapeutic effects on multiple cancer types. Additionally, there will be discussions on the cellular and molecular mechanisms of Ampligen in oncology and its potential as a therapy for endometriosis. The presentations will feature data from the Phase 2 DURIPANC study, which is evaluating the combination of Ampligen and AstraZeneca's durvalumab in treating metastatic pancreatic cancer. Preliminary data suggest Ampligen may improve survival outcomes in this context. Results are to be presented at the symposium.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506750-en) on August 06, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.